FDA Sought To Suppress Vioxx Safety Data, Sen. Grassley Says

Based upon Finance Committee investigators’ interview with FDA Office of Drug Safety’s David Graham, Grassley maintains the agency delayed presentation of a study that found an increased cardiovascular risk associated with Vioxx.